Top
Main

All Outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Sotrovimab  COVID-19 treatment studies for Sotrovimab  C19 studies: Sotrovimab  Sotrovimab   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Supplementary Data — Sotrovimab for COVID-19: real-time meta analysis of 12 studies
Covid Analysis, December 2022
https://c19early.org/vmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 80% 0.20 [0.01-4.16] death 0/528 2/529 Improvement, RR [CI] Treatment Control Gupta (DB RCT) 89% 0.11 [0.01-2.06] ventilation 0/528 4/529 Gupta (DB RCT) 75% 0.25 [0.11-0.57] progression 7/528 28/529 Gupta (DB RCT) 79% 0.21 [0.09-0.50] death/hosp. 6/528 30/529 Ong 61% 0.39 [0.05-2.90] death 1/19 10/75 Ong 56% 0.44 [0.11-1.73] ICU 2/19 18/75 Ong 59% 0.41 [0.17-0.99] progression 19 (n) 75 (n) Aggarwal (PSM) 89% 0.11 [0.00-0.79] death 0/522 15/1,563 Aggarwal (PSM) 62% 0.38 [0.20-0.67] hosp. 11/522 89/1,563 Zaqout -165% 2.65 [0.60-11.3] progression 4/345 3/583 Aggarwal 38% 0.62 [0.07-2.77] death 1/1,542 7/3,663 Aggarwal 18% 0.82 [0.56-1.18] hosp. 39/1,542 116/3,663 Aggarwal -3% 1.03 [0.80-1.29] progression 93/1,542 224/3,663 Piccicacco 66% 0.34 [0.01-8.13] death 0/88 1/90 Piccicacco 35% 0.65 [0.26-1.60] hosp. 7/88 11/90 Piccicacco 66% 0.34 [0.14-0.76] hosp./ER 7/88 21/90 Piccicacco 90% 0.10 [0.01-0.78] progression 1/88 10/90 Kneidinger -20% 1.20 [0.64-2.27] severe case 21/125 13/93 Cheng (PSM) 88% 0.12 [0.06-0.24] death Cheng (PSM) 61% 0.39 [0.36-0.43] hosp. Suzuki -8% 1.08 [0.69-1.70] progression 672 (n) 1,257 (n) Brown -258% 3.58 [0.73-17.5] hosp. 6/186 2/222 Zheng 50% 0.50 [0.31-0.81] death/hosp. 34/3,331 61/2,689 OT​1 Zheng 46% 0.54 [0.33-0.88] death/hosp. 32/3,331 55/2,689 OT​1 Self (DB RCT) -2% 1.02 [0.48-2.17] death 14/182 13/178 Self (DB RCT) 11% 0.89 [0.73-1.10] no recov. 22/160 27/178 Self (DB RCT) 7% 0.93 [0.63-1.35] no recov. 160 (n) 178 (n) Sotrovimab COVID-19 outcomes c19early.org/v Dec 2022 1 OT: comparison with other treatment Favors sotrovimab Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit